establish
cell
culturederiv
vaccin
product
requir
develop
appropri
downstream
process
today
mani
downstream
method
appli
origin
eggderiv
product
process
method
often
slightli
modifi
order
account
new
demand
howev
effort
current
underway
optim
process
focus
exampl
ion
exchang
affin
base
membran
adsorpt
chromatographi
review
cover
main
aspect
relev
downstream
process
egg
mammalian
cell
culturederiv
whole
influenza
virus
two
hundr
year
ago
english
physician
edward
jenner
develop
first
human
vaccin
sinc
jenner
time
advanc
immunolog
led
enhanc
understand
human
immun
system
elimin
invad
bacteria
virus
princip
vaccin
induct
prime
state
vaccin
person
anim
follow
exposur
pathogen
fast
secondari
immun
respons
gener
enabl
challeng
host
acceler
elimin
infecti
particl
protect
clinic
diseas
sever
type
vaccin
live
vaccin
gener
base
attenu
heterolog
recombin
infecti
virus
live
organ
inactiv
vaccin
inactiv
prepar
viru
particl
subcellular
fraction
split
vaccin
specif
protein
subunit
vaccin
viru
vaccin
also
base
synthet
peptid
recombin
vector
plasmid
dna
today
larg
number
vaccin
use
control
outbreak
diseas
like
measl
mump
rubella
polio
hepat
b
yellow
fever
rabi
human
papillomaviru
induc
cancer
rotaviru
gastroenter
influenza
due
annual
death
rate
potenti
caus
pandem
influenza
remain
major
public
health
concern
current
strategi
control
influenza
outbreak
mainli
center
prophylact
vaccin
conjunct
antivir
medic
case
influenza
distinguish
season
pandem
vaccin
season
influenza
vaccin
commonli
trival
dose
contain
three
differ
strain
influenza
b
virus
strain
subject
annual
chang
recommend
world
health
organ
pandem
influenza
vaccin
contain
respect
pandem
viru
subtyp
precis
predict
subtyp
possibl
far
therefor
small
number
dose
stockpil
product
larg
quantiti
initi
pandem
influenza
subtyp
identifi
human
tradit
influenza
vaccin
produc
embryon
chicken
egg
process
sever
drawback
lack
scalabl
risk
involv
allerg
reaction
induc
egg
protein
addit
challeng
produc
avian
pandem
strain
fertil
egg
disadvantag
led
develop
mammalian
cell
cultur
base
product
process
current
sever
cell
line
use
product
influenza
virus
exampl
vero
cell
mdck
cell
establish
cell
culturederiv
vaccin
product
requir
develop
appropri
downstream
process
today
mani
downstream
method
appli
origin
eggderiv
product
process
method
often
slightli
modifi
order
account
new
demand
howev
effort
current
underway
optim
process
focus
exampl
ion
exchang
affin
base
membran
adsorpt
chromatographi
review
articl
cover
main
aspect
relev
downstream
process
egg
mammalian
cell
culturederiv
whole
influenza
virus
major
current
avail
human
influenza
vaccin
split
subunit
vaccin
vaccin
membran
protein
hemagglutinin
requir
membran
fraction
gener
deriv
concentr
purifi
viru
particl
deterg
solubil
altern
vaccin
base
attenu
whole
influenza
virus
howev
case
separ
cell
debri
purif
viru
particl
first
step
vaccin
product
influenza
viru
particl
consist
host
cell
membran
deriv
lipid
bilay
envelop
viru
encod
glycoprotein
hemagglutinin
ha
neuraminidas
na
matrix
protein
embed
ha
na
form
spike
protrud
membran
separ
influenza
viru
cultur
medium
allanto
fluid
base
either
size
viru
particl
properti
outer
membran
compar
contamin
compon
viru
harvest
downstream
process
purif
influenza
virus
gener
subdivid
illustr
fig
prior
first
concentr
step
larg
contamin
remov
cultiv
broth
allanto
fluid
concentr
method
center
ultracentrifug
ultrafiltr
diafiltr
chromatograph
method
base
ion
exchang
specif
affin
past
also
shown
influenza
virus
success
concentr
alcohol
polyethylen
glycol
precipit
concentr
process
densiti
gradient
ultracentrifug
type
chromatograph
method
product
egg
mammalian
cellderiv
inactiv
influenza
vaccin
step
commonli
follow
inactiv
step
gener
done
chemic
use
formalin
binari
ethyleneimin
bei
bpropiolacton
bpl
compli
regulatori
requir
host
cell
dna
level
major
product
process
includ
dnaas
treatment
procedur
frequent
combin
chemic
inactiv
sequenti
order
remov
appli
compon
dna
fragment
residu
contamin
affin
ion
exchang
chromatographi
andor
diafiltr
conduct
final
purif
step
case
split
subunit
vaccin
membran
purifi
viru
particl
deterg
solubil
target
product
isol
howev
latter
unit
oper
subject
review
influenza
vaccin
product
process
method
evalu
broad
rang
assay
includ
infect
antigen
ha
activ
steril
innocu
residu
level
host
cell
dna
protein
viral
infect
typic
assay
vitro
tissu
cultur
infect
dose
tcid
vivo
infect
rate
mice
chick
embryo
ld
antigen
often
character
guineapig
ferret
mice
antigen
potenc
assay
singl
inject
viru
prepar
ha
inhibit
assay
anim
blood
sampl
ha
activ
assay
reflect
activ
viru
particl
agglutin
erythrocyt
compar
robust
respect
chang
start
materi
buffer
composit
sampl
matrix
addit
often
possibl
obtain
close
materi
balanc
therefor
assay
allow
quantit
comparison
individu
unit
oper
hand
data
obtain
may
directli
compar
strain
strain
product
whole
viru
vaccin
furthermor
result
necessarili
correl
determin
ha
antigen
content
final
product
specifi
european
pharmacopoeia
immunochem
method
requir
ha
quantif
current
mainli
done
singl
radial
immunodiffus
assay
srid
elisa
assay
hplc
method
establish
well
level
residu
contamin
gener
evalu
total
protein
dsdna
assay
virtual
chromatograph
purif
influenza
virus
perform
product
scale
use
concentr
allanto
fluid
cultiv
broth
start
materi
concentr
step
classic
base
centrifug
recent
year
method
frequent
substitut
differ
type
ultrafiltr
diafiltr
elford
andrew
demonstr
influenza
virus
could
concentr
highspe
centrifug
earli
similar
method
describ
evalu
concentr
eggderiv
influenza
virus
even
today
use
densiti
gradient
centrifug
common
product
eggderiv
cell
culturederiv
influenza
vaccin
precis
method
mainli
depend
appli
equip
gener
harvest
allanto
fluid
cultiv
broth
clarifi
lowspe
centrifug
viru
subsequ
sediment
ultracentrifug
step
pellet
viru
suspend
method
allow
swell
purifi
concentr
viru
centrifug
viru
solut
centrifug
sucros
gradient
precis
gradient
rang
vari
major
public
describ
gradient
rang
target
viru
sucros
sucros
subsequ
remov
pellet
viru
reimer
et
al
gerin
anderson
introduc
zonal
ultracentrifug
method
improv
puriti
harvest
viru
effici
method
reimer
et
al
demonstr
method
allow
tenfold
concentr
viru
respect
allanto
fluid
approxim
purif
respect
protein
content
diafiltr
ultrafiltr
cross
flow
microfiltr
frequent
use
biotechnolog
industri
order
remov
concentr
insolubl
larger
particl
suspend
medium
import
paramet
concentr
whole
viru
particl
permeat
flux
transmembran
pressur
pore
size
process
effici
increas
pore
size
permeat
flux
howev
order
minim
viru
loss
pore
size
chosen
significantli
smaller
viru
particl
increas
permeat
flux
result
high
wall
shear
rate
sinc
influenza
virus
fragil
could
lead
damag
viru
particl
therefor
safeti
margin
empir
defin
appli
process
first
purif
studi
influenza
virus
allanto
fluid
describ
appli
collodion
membran
averag
pore
diamet
rang
nm
mice
infect
test
indic
influenza
retain
averag
pore
diamet
nm
less
influenza
b
lee
diamet
nm
due
simplic
process
method
gain
increas
interest
last
year
concentr
virus
eg
adenoviru
adenoassoci
virus
murin
leukemia
viru
lentiviru
parvoviru
bromoviru
influenza
viru
nayak
et
al
describ
ultrafiltr
mdck
cellderiv
equin
influenza
viru
particl
platetyp
flat
sheet
polyethersulfon
membran
kda
mw
cutoff
prior
concentr
cell
cultur
broth
clarifi
via
depth
filtrat
lm
pore
size
inactiv
bei
base
ha
activ
assay
obtain
approxim
concentr
factor
retent
total
ha
recoveri
total
protein
host
cell
dna
reduct
report
respect
wickramasingh
et
al
test
differ
ultrafiltr
sartoconslic
cassett
concentr
human
influenza
membran
made
polyethersulfon
nomin
filtrat
surfac
area
pore
size
rang
kda
lm
test
viru
produc
mdck
cell
maintain
serumfre
medium
viru
particl
clarifi
depth
filtrat
lm
pore
size
prior
bpl
inactiv
identifi
optim
pore
size
kda
use
wall
shear
rate
experiment
condit
viru
loss
base
ha
activ
assay
neglig
total
protein
host
cell
dna
reduct
report
respect
case
membran
pore
size
close
viru
particl
lm
observ
intern
foul
indic
import
care
select
optim
membran
pore
size
oper
condit
kalbfuss
et
al
test
three
differ
polysulfon
hollowfib
modul
cutoff
kda
lm
lm
appli
viru
sampl
produc
similar
condit
mdck
serumfre
describ
experi
conduct
wickramasingh
et
al
howev
clarif
slightli
differ
primari
clarif
done
depth
filtrat
lm
prior
bpl
inactiv
inactiv
precipit
remov
microfiltr
step
lm
lm
hollow
fiber
membran
retain
viru
lm
kda
hollow
fiber
membran
howev
retain
viru
recoveri
retent
respect
total
protein
host
cell
dna
reduct
lm
hollow
fiber
membran
given
kda
hollow
fiber
membran
respect
summari
ultra
microor
cross
flow
filtrat
repres
power
tool
largescal
concentr
complex
biomolecul
like
virus
viral
vector
howev
care
select
membran
cutoff
oper
condit
essenti
order
maxim
benefit
oper
concentr
viral
product
present
studi
exclus
limit
identifi
influenza
virus
vari
mammalian
cellderiv
viru
particl
kda
exclus
limit
eggderiv
viru
particl
approxim
nm
diamet
influenza
virus
rang
nm
howev
influenza
virus
tendenc
aggreg
size
distribut
viru
aggreg
mdck
cellderiv
viru
particl
rang
nm
even
lm
degre
aggreg
seem
depend
product
process
account
vari
start
materi
fact
rate
procedur
pore
differ
supplier
variat
exclus
limit
influenza
virus
elimin
rate
contamin
expect
process
effici
increas
larger
pore
size
allow
higher
degre
protein
host
cell
nucleic
acid
elimin
larger
pore
size
reduc
permeat
flux
also
reduc
wall
shear
rate
fragil
viru
particl
subject
concentr
step
henc
optim
exclus
limit
oper
condit
everi
process
still
identifi
empir
base
product
recoveri
concentr
factor
achiev
elimin
contamin
addit
target
product
whole
viru
particl
viral
fragment
elimin
step
hand
split
vaccin
subunit
vaccin
produc
pore
size
chosen
includ
viral
fragment
product
fraction
order
increas
overal
yield
current
precipit
appli
largescal
product
process
report
influenza
vaccin
past
precipit
ethyl
methyl
alcohol
polyethylen
glycol
describ
eggderiv
influenza
virus
due
simplic
unit
oper
potenti
largescal
oper
l
work
volum
seem
awaken
interest
precipit
contamin
like
host
cell
dna
protein
primari
purif
step
howev
econom
effici
precipit
agent
contamin
target
viru
still
identifi
size
exclus
chromatographi
sec
separ
molecul
base
hydrodynam
volum
size
influenza
virus
tendenc
form
aggreg
discuss
previou
section
molecular
weight
influenza
virion
typic
exce
kda
convers
molecular
weight
solubl
biopolym
larger
hundr
kda
henc
sizebas
fraction
offer
promis
approach
separ
viru
particl
contamin
host
cell
protein
nucleic
acid
demonstr
turkey
coronaviru
vesicular
stomat
viru
influenza
viru
due
size
viru
particl
abl
penetr
pore
chromatographi
media
henc
elut
void
volum
column
use
heyward
et
al
appli
control
pore
glass
cpg
pore
size
purif
eggderiv
influenza
viru
aann
polyethylen
glycol
precipit
expect
size
influenza
viru
particl
virion
elut
void
volum
contamin
protein
well
separ
viral
fraction
lead
typic
doubl
peak
uv
spectrum
overal
recoveri
cpgsec
load
viru
infect
puriti
viru
prepar
compar
viru
prepar
purifi
convent
densiti
gradient
procedur
judg
sdspage
recent
applic
sec
report
purif
equin
human
influenza
viru
particl
nayak
et
al
separ
bei
inactiv
mdck
cellderiv
equin
influenza
viru
particl
concentr
cultiv
broth
sepharos
chromatographi
accord
manufactur
datasheet
fraction
rang
sepharos
kda
henc
whole
virion
aggreg
virion
elut
void
volum
small
solut
retain
sec
medium
lead
doubl
peak
uv
trace
shown
nayak
et
al
base
ha
activ
viral
recoveri
void
volum
sec
process
concentr
approxim
remain
ha
activ
distribut
later
fraction
like
account
deterior
virion
small
membran
fragment
contain
ha
molecul
therefor
conclud
sec
allow
fraction
whole
virion
damag
viral
cellular
membran
particl
due
bud
process
influenza
virus
membran
structur
particl
ident
whole
viru
particl
typic
viru
fraction
void
volum
collect
process
base
concentr
start
materi
nayak
et
al
achiev
total
protein
host
cell
dna
reduct
fraction
respect
combin
ultrafiltr
step
sec
overal
viru
recoveri
protein
dna
reduct
respect
kalbfuss
et
al
compar
four
differ
sec
media
sepharos
sepharos
sepharos
superdex
prep
grade
pg
exclus
limit
nm
mda
mda
kda
consequ
intact
viru
particl
could
penetr
pore
chromatographi
media
model
author
use
bpl
inactiv
mdck
cell
culturederiv
serumfre
medium
human
influenza
viru
particl
concentr
cultiv
broth
elut
test
chromatographi
media
led
previou
studi
characterist
doubl
peak
pattern
uv
trace
first
peak
void
volum
repres
viral
fraction
second
peak
result
elut
small
solut
like
protein
amino
acid
nucleotid
etc
addit
kalbfuss
et
al
abl
demonstr
host
cell
dna
larger
contamin
protein
consequ
elut
earlier
small
contamin
test
chromatographi
media
host
cell
dna
coelut
viru
fraction
quantiti
coelut
dna
steadili
increas
sepharos
sepharos
ff
sepharos
ff
superdex
pg
hand
viral
fraction
heavili
tail
case
sepharos
clearli
suggest
damag
viru
cellular
membran
particl
abl
enter
fraction
pore
alreadi
describ
nayak
et
al
therefor
author
select
sepharos
ff
studi
achiev
overal
viru
product
yield
base
sec
load
total
protein
host
cell
dna
reduct
respect
overal
yield
present
studi
vari
tremend
recoveri
achiev
cpg
sepharos
sepharos
howev
consid
start
materi
term
influenza
viru
strain
product
process
egg
versu
mdck
cellderiv
time
harvest
clarif
concentr
precipit
ultrafiltr
differ
studi
particular
clarif
concentr
step
result
viru
particl
damag
therefor
accumul
viral
breakdown
product
differenti
whole
virion
major
analyt
assay
also
appli
small
cell
debri
remain
cultur
broth
clarif
particl
separ
whole
viru
particl
sec
lead
appar
low
recoveri
product
fraction
addit
point
consid
context
degrad
viru
particl
unspecif
proteas
activ
toward
end
upstream
process
due
cell
lysi
storag
condit
harvest
inactiv
concentr
asid
consider
overal
yield
cpg
sepharos
ff
studi
compar
consid
yield
sec
purifi
sepharos
vesicular
stomat
viru
moloney
murin
leukemia
viru
extrem
low
yield
nayak
et
al
might
repres
method
use
one
possibl
explan
low
yield
obvious
tail
void
volum
peak
appli
sepharos
describ
nayak
et
al
kalbfuss
et
al
henc
puriti
viru
particl
balanc
yield
particular
case
sepharos
summari
sec
allow
separ
whole
virion
viru
cellular
membran
particl
influenza
virus
envelop
bud
plasma
membran
henc
membran
composit
whole
virion
ident
viru
cellular
debri
make
separ
challeng
chromatograph
method
like
affin
chromatographi
optim
process
yield
achiev
howev
contrast
veterinari
vaccin
product
puriti
sec
fraction
usual
suffici
human
vaccin
product
level
contamin
protein
host
cell
dna
need
reduc
addit
unit
oper
order
compli
regulatori
requir
addit
use
sec
unit
oper
might
econom
feasibl
largescal
product
process
due
restrict
column
size
stabil
gel
matric
limit
load
volum
ion
exchang
chromatographi
iec
reli
charg
charg
interact
viral
envelop
charg
immobil
resin
target
molecul
displac
chromatographi
media
increas
ionic
strength
altern
adsorb
target
elut
chang
ph
lead
case
influenza
virus
unfavor
overal
charg
viral
envelop
matrix
target
bind
howev
requir
chang
ph
ionic
strength
complet
elut
affect
product
activ
structur
stabil
virion
influenza
virus
gener
sensit
ph
chang
particular
acid
condit
compar
stabl
presenc
high
salt
concentr
henc
one
import
point
consid
type
chromatographi
product
stabil
run
condit
use
iec
subdivid
cation
cec
anion
exchang
chromatographi
aec
method
appli
posit
mode
ie
viru
particl
adsorb
chromatographi
medium
neg
mode
ie
contamin
adsorb
matrix
virion
bind
differ
variat
cec
aec
appli
purif
influenza
virus
allanto
fluid
cell
cultur
broth
howev
due
acid
pi
influenza
virion
possibl
loss
ha
activ
lower
ph
anion
exchang
resin
commonli
favor
neurath
et
al
demonstr
applic
cation
exchang
separ
influenza
virus
allanto
fluid
interestingli
could
demonstr
type
ion
exchang
also
ionic
form
influenc
adsorpt
behavior
viru
chromatographi
medium
bind
differ
eggderiv
influenza
viru
type
taiwan
ann
compar
sodium
calcium
form
cation
exchang
type
influenza
viru
subtyp
bind
sodium
form
adsorb
calcium
form
resin
could
therefor
separ
larg
amount
contamin
protein
allanto
fluid
howev
b
strain
viru
fail
adsorb
either
form
resin
henc
method
use
gener
vaccin
product
process
neurath
et
al
also
demonstr
product
stabil
via
potenc
test
mice
differ
observ
crude
purifi
virus
unfortun
ha
activ
assay
common
assay
allow
quantit
evalu
method
carri
matheka
armbrust
compar
anion
cation
exchang
resin
purif
eggderiv
viru
particl
influenza
expect
pi
influenza
virion
anion
exchang
shown
suitabl
adsorb
influenza
virus
ph
condit
close
neutral
furthermor
matheka
armbrust
test
effect
bead
size
well
basic
anion
exchang
anticip
bead
size
relev
separ
influenza
virion
contamin
protein
hand
known
bead
pore
size
bead
contribut
overal
capac
appli
resin
particular
purif
larg
particl
howev
describ
author
test
basic
affect
adsorpt
behavior
viru
particl
higher
basic
greater
ionic
strength
requir
displac
virus
followup
public
matheka
armbrust
demonstr
fraction
influenza
virus
elut
adsorb
virion
anion
exchang
resin
amberlit
ira
increas
nacl
concentr
elut
buffer
citrat
buffer
ph
compar
three
eggderiv
influenza
viru
type
blee
author
observ
clear
differ
adsorpt
characterist
strain
agreement
studi
henc
close
attent
paid
viral
strain
appli
ion
exchang
chromatographi
process
one
addit
interest
find
variat
viru
particl
diamet
nm
elut
larger
viru
particl
nm
viru
aggreg
elut
fraction
low
ionic
strength
small
virion
nm
high
salt
concentr
accord
later
observ
henc
larger
virion
seem
bind
less
tightli
chromatograph
media
smaller
one
like
due
spheric
shape
viru
particl
contact
area
chromatograph
support
increas
proport
size
virion
therefor
larger
virion
elut
lower
ionic
strength
iordan
et
al
describ
downstream
process
scheme
compris
weak
deaesephadex
anion
exchang
concentr
step
via
ultrafiltr
kda
cutoff
desalt
step
via
sec
sepharos
use
two
eggderiv
influenza
strain
model
strain
achiev
overal
recoveri
approxim
volumetr
concentr
factor
slight
differ
could
observ
protein
remov
rate
total
protein
reduct
vari
respect
differ
like
due
shift
ionic
strength
requir
desorpt
viru
particl
influenza
viru
strain
requir
higher
nacl
concentr
order
elut
deaesephadex
fact
util
wash
step
wash
nacl
combin
nacl
result
case
high
product
puriti
total
protein
remov
mainli
due
aec
unit
oper
follow
concentr
desalt
step
account
margin
overal
protein
reduct
howev
ha
activ
loss
mainli
due
two
unit
oper
small
amount
viru
particl
lost
aec
viru
particl
lost
column
load
wash
might
larger
viral
aggreg
bind
less
tightli
ion
exchang
resin
accord
literatur
differ
adsorpt
characterist
two
strain
could
due
variat
overal
surfac
charg
aggreg
behavior
viru
particl
could
also
caus
differ
adsorpt
characterist
viral
strain
protein
allanto
fluid
cell
cultur
media
differ
could
reduc
use
proteinfre
media
upstream
process
case
cell
culturederiv
viru
particl
nevertheless
today
elut
condit
aec
determin
empir
everi
strain
influenza
viru
aec
process
iordan
et
al
compar
aec
combin
concentr
sec
unit
oper
downstream
process
base
sucros
gradient
centrifug
overal
yield
influenza
strain
significantli
reduc
degre
viral
aggreg
higher
case
gradient
centrifug
method
consider
differ
degre
protein
reduct
method
howev
volumetr
concentr
factor
centrifug
method
two
three
time
higher
compar
aec
base
process
cours
due
ultrafiltr
step
follow
aec
optim
reduc
retent
volum
increas
oper
time
reduc
dead
volum
appli
ultrafiltr
equip
iec
studi
describ
far
center
purif
eggderiv
influenza
viru
particl
howev
although
result
directli
transfer
downstream
process
cell
culturederiv
virion
offer
good
start
point
design
correspond
unit
oper
kalbfuss
et
al
investig
suitabl
aec
sec
order
remov
residu
host
cell
dna
posit
neg
mode
test
two
differ
sepharos
q
base
ion
exchang
matric
sepharos
q
ff
sepharos
q
xl
separ
dna
mdck
cellderiv
human
influenza
viru
bpl
inactiv
nacl
phosphat
buffer
ph
use
displac
posit
mode
aec
applic
media
display
differ
select
respect
viru
particl
host
cell
dna
sepharos
q
ff
separ
viru
host
cell
dna
partial
separ
achiev
sepharos
q
xl
use
sepharos
q
xl
led
split
peak
elut
desorb
viru
one
elut
peak
coelut
host
cell
dna
appli
aec
neg
mode
load
buffer
condit
nacl
result
flow
viru
particl
recoveri
base
load
howev
overal
yield
depend
amount
load
viru
reduc
yield
observ
low
load
like
due
residu
bind
capac
stationari
phase
natur
load
close
column
capac
also
result
reduc
yield
altern
bead
chromatographi
membran
adsorb
increasingli
use
purif
larg
particl
ie
virus
kalbfuss
et
al
test
anion
exchang
membran
adsorb
aex
direct
captur
clarifi
lm
bpl
inactiv
human
equin
influenza
viru
particl
studi
use
sartobind
q
membran
adsorb
compar
differ
product
system
well
viru
harvest
cultiv
serumfre
serumcontain
media
sartobind
membran
base
stabil
reinforc
cellulos
pore
size
lm
function
group
sartobind
sartobind
q
diethylamin
weak
aex
quaternari
ammonium
strong
aex
respect
result
obtain
indic
aex
suitabl
captur
influenza
virus
case
viral
displac
could
achiev
shift
ph
howev
elut
nacl
result
almost
complet
elut
sartobind
q
compar
sartobind
q
displac
sartobind
result
significantli
lower
recoveri
delay
onset
elut
ie
elut
occur
higher
salt
concentr
henc
viru
particl
interact
stronger
sartobind
sartobind
q
membran
probabl
due
charg
densiti
lmol
cm
higher
sartobind
q
lmol
cm
like
higher
charg
densiti
sartobind
lead
higher
capac
case
small
colloid
also
result
increas
number
interact
site
therefor
bind
strength
virion
stationari
phase
author
report
overal
recoveri
sartobind
q
sartobind
membran
adsorb
respect
high
loss
sartobind
contrast
find
iordan
et
al
similar
beadbas
separ
observ
tail
explain
variat
size
viru
particl
due
aggreg
complex
bud
process
breakdown
product
viru
particl
process
sartobind
q
allow
signific
reduct
total
protein
content
howev
due
broad
elut
viru
particl
possibl
separ
viru
contamin
host
cell
dna
comparison
purif
viru
harvest
produc
serumfre
serumcontain
media
indic
higher
capac
latter
medium
explain
shift
adsorpt
equilibrium
could
due
differ
ionic
strength
adsorpt
competitor
respect
medium
hand
neither
viru
type
human
equin
cultiv
system
roller
bottl
stir
tank
show
signific
effect
membran
capac
drawback
shown
studi
low
concentr
factor
approxim
seven
like
caus
tail
elut
peak
slow
desorpt
kinet
viru
particl
reduct
flow
rate
even
incub
viru
desorpt
buffer
would
overcom
problem
also
reduc
process
product
howev
product
l
h
sartobind
q
remark
high
compar
chromatograph
media
even
cross
flow
ultrafiltr
oper
interest
observ
respect
use
aex
report
goyal
et
al
observ
adsorpt
eggderiv
influenza
viru
aex
zeta
plu
filter
seri
depend
ph
feed
maximum
capac
observ
ph
strong
declin
toward
acid
ph
maximum
capac
ph
less
pronounc
declin
toward
alkalin
ph
appli
immedi
neutral
elut
full
recoveri
achiev
base
ha
activ
differ
basic
elut
buffer
summari
iec
excel
tool
captur
purif
egg
cell
culturederiv
influenza
viru
particl
aec
gener
suitabl
adsorpt
viru
particl
howev
nucleic
acid
also
bind
aec
resin
make
effici
separ
viru
particl
host
cell
dna
challeng
reduct
level
host
cell
dna
contamin
protein
aec
strongli
depend
influenza
viru
strain
capac
aec
media
strongli
affect
type
contamin
protein
amount
nucleic
acid
resin
capac
improv
optim
load
wash
condit
ph
ionic
strength
order
reduc
adsorpt
contamin
compon
howev
ph
sensit
viru
particl
limit
option
process
design
interest
effect
mention
possibl
separ
larger
viru
aggreg
smaller
viru
particl
aec
could
potenti
allow
separ
viral
membran
fragment
whole
viru
particl
could
relev
product
live
vaccin
viral
membran
fraction
often
elimin
filtrat
procedur
affin
chromatographi
ac
allow
purif
biomolecul
basi
individu
chemic
structur
biolog
function
target
molecul
separ
base
revers
interact
specif
ligand
immobil
chromatographi
medium
ac
offer
excel
specif
combin
high
capac
chromatographi
media
like
membran
adsorb
repres
power
unit
oper
captur
biomolecul
moreov
respect
chromatograph
method
ac
offer
unmatch
simplic
oper
case
influenza
viru
particl
ligand
target
commonli
ha
na
ha
major
influenza
viru
surfac
glycoprotein
mediat
via
sialic
acid
bind
pocket
attach
viru
host
cell
henc
potenti
ligand
ac
influenza
virus
antibodi
specif
ha
na
sialic
acid
sialic
acid
deriv
lectin
interfer
glycan
residu
glycoprotein
ha
na
altern
ligand
would
peptid
small
molecul
specif
ha
na
use
classic
immunoaffin
chromatographi
describ
whole
influenza
viru
particl
deterg
solubil
viral
ha
na
sweet
et
al
describ
purif
eggderiv
whole
influenza
virus
kong
polyclon
rabbit
antibodi
elut
viru
particl
done
alkalin
buffer
ph
rang
howev
infect
elut
fraction
load
materi
like
due
high
ph
shown
reduc
viral
infect
ha
activ
unfortun
ph
requir
elut
target
product
depend
appli
antibodi
applic
polyclon
antibodi
allow
broader
specif
differ
subtyp
influenza
virus
bind
kinet
strength
might
suboptim
immuno
ac
gerent
et
al
appli
specif
monoclon
antibodi
purif
deterg
solubil
ha
na
eggderiv
influenza
virus
reassort
influenza
viru
glycoprotein
abl
elut
ha
molecul
ph
loss
ha
activ
na
molecul
releas
acid
ph
ph
result
activ
loss
anoth
concern
immuno
ac
limit
number
process
cycl
fact
biolog
ligand
usual
withstand
harsh
clean
sanit
condit
sweet
et
al
observ
limit
oper
lifetim
ten
cycl
column
signific
econom
disadvantag
product
process
hand
common
problem
major
biolog
affin
media
ha
glycoprotein
contain
sever
nlink
glycosyl
side
glycan
target
affin
ligand
specif
lectin
lectin
class
carbohydratespecif
protein
glycoprotein
mainli
bind
monosaccharid
short
oligosaccharid
sequenc
nonreduc
termini
glycan
henc
specif
characterist
glycan
compar
contamin
molecul
util
purif
whole
influenza
virus
viral
subunit
recombin
ha
lectin
screen
opitz
et
al
show
mdck
cellderiv
whole
influenza
virus
effici
isol
cultiv
broth
ac
base
lectin
euonymu
europaeu
lectin
bind
oligosaccharid
contain
galactosyl
galactos
residu
target
molecul
displac
lactos
necessari
lactos
contain
nacl
studi
opitz
et
al
use
human
influenza
viru
propag
mdck
cell
maintain
serumcontain
medium
overal
recoveri
viru
particl
heavili
depend
appli
chromatographi
matrix
maximum
recoveri
approxim
load
viru
achiev
cellulos
membran
particular
case
total
protein
host
cell
dna
reduct
base
start
materi
amount
respect
experi
show
method
applic
rang
differ
human
influenza
viru
strain
well
influenza
b
unpublish
data
henc
method
reflect
effici
captur
step
mdck
cellderiv
influenza
virus
howev
consid
glycosyl
pattern
ha
glycan
strongli
depend
host
cell
frequent
describ
literatur
recombin
protein
biotechnolog
product
suitabl
lectin
identifi
virus
produc
differ
host
cell
differ
cultiv
condit
differ
product
system
like
fertil
egg
gener
concern
associ
ac
leach
bioactiv
compound
account
particular
lectin
potenti
toxic
therefor
fda
insist
biolog
affin
ligand
use
manufactur
process
biolog
product
meet
applic
requir
end
product
one
possibl
solut
overcom
disadvantag
biolog
ligand
mention
applic
small
molecul
immobil
sialic
acid
deriv
sialyllactos
shown
bind
differ
strain
influenza
virus
ac
base
sialic
acid
deriv
bketosid
sialic
acid
deriv
describ
purif
whole
influenza
virus
allanto
fluid
displac
viru
particl
affin
sepharos
matrix
done
benzyl
aketosid
nacetylneuramin
acid
howev
releas
kinet
prove
difficult
test
sialic
acid
deriv
result
low
total
viral
recoveri
base
ha
activ
assay
order
appli
molecul
ac
divers
librari
sialic
acid
deriv
would
screen
identifi
ligand
favor
bind
releas
kinet
dissoci
constant
usual
consid
good
work
rang
anoth
altern
pseudo
ac
base
heparin
sulfat
cellulos
latter
literatur
also
refer
iec
matrix
heparin
member
glycosaminoglycan
famili
polysaccharid
linear
carbohydr
consist
uron
acid
dglucosamin
repeat
disaccharid
subunit
heparin
heparan
sulfat
demonstr
interact
sever
virus
includ
herp
virus
dengu
viru
adenoassoci
viru
human
immunodefici
viru
type
moloney
murin
leukemia
deriv
retrovirus
influenza
viru
interact
sulfat
cellulos
ha
influenza
virus
current
fulli
understood
howev
sulfat
frequent
appli
purif
egg
cell
culturederiv
influenza
virus
recombin
ha
opitz
et
al
compar
captur
mdck
cellderiv
human
influenza
viru
sulfat
heparin
column
chromatographi
base
ha
activ
assay
viral
recoveri
sulfat
heparin
respect
unfortun
detail
provid
degre
contamin
remov
neither
studi
palach
et
al
peterka
et
al
report
applic
sulfat
column
chromatographi
led
low
viral
yield
rang
base
ha
activ
assay
tcid
assay
respect
hand
kost
suggest
sulfat
column
chromatographi
determin
viru
particl
viral
antigen
concentr
process
sampl
point
load
condit
crucial
success
applic
sulfat
depend
viru
strain
sourc
viru
particl
salt
concentr
requir
effici
adsorpt
viru
particl
often
significantli
lower
phosphat
buffer
salin
unpublish
data
major
drawback
applic
sulfat
bead
purif
influenza
virus
low
product
column
chromatographi
potenti
improv
use
specif
sulfat
reinforc
cellulos
membran
adsorb
anoth
option
would
purif
influenza
virus
small
peptid
ligand
peptid
ac
alreadi
success
use
purif
recombin
protein
prerequisit
purif
influenza
virus
identif
peptid
broad
specif
differ
influenza
type
strain
peptid
librari
immobil
chromatograph
support
one
import
consider
ac
immobil
ligand
chromatograph
support
variou
type
preactiv
chromatographi
media
commerci
avail
resin
function
chemic
reactiv
amin
aldehyd
epoxi
group
howev
verifi
ligand
immobil
function
also
access
target
particular
larg
particl
like
virus
access
crucial
account
spheric
hindranc
larger
particl
small
ligand
may
immobil
via
spacer
chromatograph
support
also
pore
size
chromatographi
media
consid
particular
high
valu
ligand
chromatographi
media
exclud
influenza
virion
due
pore
size
distribut
lead
low
bind
capac
despit
high
number
immobil
ligand
henc
larg
pore
size
media
exampl
control
pore
glass
membran
adsorb
nonpor
media
use
improv
process
economi
summari
ac
repres
excel
tool
captur
purif
influenza
virus
overal
yield
product
ac
unit
oper
mainli
depend
select
ligand
bind
releas
kinet
combin
high
capac
chromatograph
support
ac
allow
achiev
good
concentr
factor
primari
captur
step
furthermor
level
contamin
protein
host
cell
nucleic
acid
significantli
reduc
filtrat
centrifug
techniqu
allow
higher
volumetr
concentr
factor
method
lack
specif
simplic
ac
unit
oper
high
specif
unmatch
chromatograph
method
howev
level
puriti
achiev
sole
depend
specif
ligand
use
major
drawback
use
ac
high
price
ligand
potenti
leach
bioactiv
compound
limit
respect
clean
sanit
use
small
molecul
like
heparin
sulfat
glucos
molecul
eg
sulfat
help
overcom
disadvantag
also
lack
high
specif
nevertheless
sulfat
current
pseudo
ac
medium
commerci
use
product
influenza
vaccin
sever
differ
chromatographi
media
test
purif
influenza
virus
opitz
et
al
compar
numer
column
chromatographi
media
membran
adsorb
captur
influenza
virus
author
indic
capac
membran
adsorb
superior
test
beadbas
chromatographi
materi
addit
soft
gel
observ
unspecif
loss
viru
particl
case
solid
support
polym
matrix
membran
adsorb
howev
point
unspecif
loss
target
materi
observ
protein
influenza
virus
depend
type
membran
adsorb
applic
commonli
appli
chromatographi
media
influenza
purif
porou
bead
main
disadvantag
limit
mass
transfer
kinet
transport
solut
porou
lumen
bead
occur
exclus
diffus
howev
effect
diffus
low
larger
particl
ie
virion
diamet
close
pore
size
one
possibl
overcom
limit
applic
nonpor
bead
larg
porou
membran
monolith
disadvantag
nonpor
bead
low
capac
product
monolith
porou
membran
allow
overcom
disadvantag
differ
type
monolith
column
use
success
purif
tomato
mosaic
viru
moloney
murin
leukaemia
viru
influenza
viru
case
influenza
viru
particl
purif
base
anion
exchang
monolith
column
follow
sec
concentr
step
pseudoaffin
monolith
column
membran
adsorb
use
purif
viru
particl
exampl
aed
aegypti
densonucleosi
viru
densonucleosi
viru
influenza
viru
main
advantag
membran
adsorb
compar
beadbas
column
chromatographi
significantli
enhanc
mass
transfer
kinet
due
convect
flow
porou
lumen
higher
volumetr
concentr
factor
reduc
pressur
drop
oper
therefor
increas
product
howev
consid
product
also
function
bind
kinet
target
molecul
immobil
ligand
henc
case
affin
membran
adsorb
oper
flow
rate
mainli
limit
bind
releas
kinet
immobil
ligand
backpressur
appli
chromatographi
materi
hand
influenc
bind
kinet
viru
membran
crucial
ion
exchang
membran
adsorb
major
applic
lead
increas
product
lack
specif
affinitybas
purif
step
addit
membran
adsorb
compar
easi
scaleup
valid
furthermor
due
low
product
cost
econom
feasibl
integr
unit
oper
singleus
product
process
clear
advantag
current
avail
monolith
column
import
requir
content
puriti
whole
virion
inactiv
cell
culturederiv
human
influenza
vaccin
accord
european
pharmacopoeia
lg
ha
requir
per
strain
dose
total
protein
six
time
total
ha
content
vaccin
determin
assay
case
lg
protein
per
viru
strain
human
dose
bacteri
endotoxin
less
iu
per
human
dose
residu
host
cell
dna
continu
cell
line
use
viru
propag
limit
ng
per
singl
human
dose
natur
combin
differ
downstream
process
method
allow
complianc
requir
unfortun
complet
downstream
process
describ
prepar
cell
culturederiv
whole
influenza
vaccin
literatur
moreov
public
vaccin
produc
disclos
detail
make
precis
evalu
respect
method
nearli
imposs
influenza
vaccin
influvac
purifi
process
mdck
cell
supernat
multistep
downstream
process
compris
follow
unit
oper
captur
viru
particl
iec
sulfat
prefiltr
concentrationbuff
exchang
ultraand
diafiltr
nucleas
treatment
viral
inactiv
step
formaldehyd
downstream
process
vero
cell
culturederiv
influenza
vaccin
base
centrifug
step
scheme
includ
clarif
low
speed
centrifug
concentr
ultrafiltr
kda
cutoff
purif
continu
sucros
gradient
inactiv
formalin
diafiltr
remov
formalin
altern
scheme
describ
kistner
et
al
slow
speed
centrifug
clarif
follow
earli
inactiv
step
formalin
sequenti
benzonas
treatment
destroy
vero
cell
dna
inactiv
materi
concentr
ultrafiltr
kda
cutoff
clarifi
protamin
sulfat
precipit
purif
continu
flow
zonal
centrifug
sucros
gradient
final
viruscontain
fraction
concentr
diafiltr
steril
filter
unfortun
three
case
detail
provid
concern
yield
contamin
elimin
individu
unit
oper
howev
last
exampl
residu
protein
content
entir
process
less
lg
level
host
cell
dna
less
pg
per
dose
reflect
complianc
regulatori
requir
time
studi
method
purif
influenza
virus
base
centrifug
cumbersom
technic
demand
largescal
product
viru
particl
vaccin
request
puriti
econom
process
invest
cost
requir
equip
balanc
oper
cost
filtrat
chromatographybas
process
gener
scheme
downstream
process
mdck
cellderiv
human
influenza
viru
kalbfuss
et
al
base
clarif
depth
filtrat
lm
bpl
inactiv
sec
aec
result
overal
viru
yield
total
protein
host
cell
dna
remov
base
start
materi
respect
appli
sec
judg
author
effici
separ
host
cell
protein
virion
howev
even
aec
host
cell
dna
reduct
suffici
respect
requir
european
pharmacopeia
present
scheme
would
improv
optim
aec
introduc
addit
purif
step
altern
benzonas
treatment
step
reduct
host
cell
dna
level
clear
advantag
scheme
full
scalabl
virtual
independ
influenza
viru
strain
consid
remov
rate
contamin
particular
host
cell
dna
affin
captur
step
suggest
opitz
et
al
worth
mention
develop
method
captur
mdck
cellderiv
influenza
virus
lectin
ac
eel
polym
eel
reinforc
cellulos
membran
result
host
cell
dna
contamin
per
monoval
bulk
approxim
ng
amount
roughli
ng
host
cell
dna
per
trival
dose
even
though
content
host
cell
dna
captur
step
twice
much
requir
limit
achiev
singl
step
unfortun
lectinligand
optim
choic
product
process
due
potenti
toxic
high
cost
ligand
howev
altern
ligand
similar
even
higher
specif
interest
tool
captur
step
product
process
influenza
viral
vaccin
regard
subunit
split
vaccin
remain
host
cell
dna
could
remov
followup
process
hand
benzonas
treatment
might
advis
order
ensur
absenc
larger
dna
fragment
vaccin
would
also
benefici
case
host
cell
dna
associ
viru
particl
therefor
difficult
remov
convent
techniqu
suggest
adenoviru
konz
et
al
current
three
princip
type
influenza
vaccin
use
whole
viru
vaccin
split
vaccin
subunit
vaccin
subunit
vaccin
base
highli
purifi
ha
na
membran
glycoprotein
split
vaccin
consist
viral
membran
fraction
contain
antigen
unit
oper
describ
review
focus
purif
whole
viru
particl
case
split
subunit
vaccin
membran
fraction
viral
glycoprotein
ha
na
deriv
deterg
solubil
step
separ
viru
particl
henc
method
discuss
isol
purif
intact
influenza
viru
particl
import
product
whole
viru
vaccin
split
subunit
vaccin
review
describ
wide
varieti
downstream
process
method
purif
influenza
viru
particl
deriv
egg
cell
cultur
system
result
differ
vaccin
product
system
particular
due
signific
differ
analyt
evalu
method
direct
comparison
individu
unit
oper
almost
imposs
comprehens
evalu
costeffect
perform
complet
downstream
process
influenza
viru
purif
quantiti
ha
residu
level
contamin
relev
howev
major
unit
oper
describ
review
evalu
varieti
assay
includ
infect
ha
activ
henc
direct
quantit
comparison
describ
downstream
process
influenza
viru
vaccin
product
hardli
possibl
evalu
describ
method
option
select
chromatographi
materi
visionari
scheme
gener
econom
influenza
vaccin
product
process
whole
inactiv
influenza
vaccin
shown
fig
includ
clarif
remov
larger
particl
cultiv
broth
via
depth
filtrat
follow
inlin
captur
step
viru
particl
affin
membran
adsorb
membran
adsorb
high
specif
bind
virion
larg
pore
size
achiev
flow
characterist
high
product
optim
ligand
densiti
high
capac
next
step
would
chemic
inactiv
viru
particl
follow
nucleic
acid
digest
benzonas
treatment
final
diafiltrationultrafiltr
step
could
includ
remov
residu
compound
concentr
final
harvest
blend
howev
highli
specif
strain
independ
ligand
optim
captur
process
yet
identifi
case
anion
exchang
chromatographi
appli
captur
addit
purif
step
ad
